RET Fusion Targeted Therapies Market Set for Robust Growth by 2034 Amid Precision Oncology Shift | DelveInsight
PR Newswire —
The RET fusion-targeted therapy market is set for strong expansion, driven by growing awareness of the oncogenic role of RET gene fusions and encouraging clinical trial outcomes. With the approval of targeted agents such as selpercatinib and pralsetinib for RET fusion-positive tumors,...